Facible BioDiagnostics
About this raise
Facible BioDiagnostics is raising funds on Rialto Markets through Reg A+ crowdfunding. The company has developed a new technology for diagnostic testing to deliver fast and accurate results in the detection of viruses, bacteria, and other contaminants. The technology is called Quantum-Logic Anazyme Analyte Detection (Q-LAAD) and is specifically used for COVID testing. Facible BioDiagnostics has signed an LOI with a distributor for 18 million units and estimates its gross profit margin to be 93.57%. Steven Burden, Clementine Gibard Bohachek, and Hunter Covert founded Facible BioDiagnostics in 2022. The current crowdfunding campaign has a maximum target of $40,000,000. The campaign proceeds will be used for research and development, clinical testing, and working capital.
Investment Overview
Deal Terms
- Platform
- Rialto Markets
- Start Date
- 07/28/2022
- Close Date
- 03/17/2023
$1,000
$40,000,000
$1,000
Equity - Common
Growth Stage
RegA+
$5.80
$702,724,398
Company & Team
Company
- Year Founded
- 2022
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- High
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $4,692,740
- VC Backed?
- Yes
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 03/17/2023 | Rialto Markets | $702,724,398 | - | Equity - Common | Not Funded | RegA+ |